FYN deficiency in the presence of BCR/ABL expression is a mediator of chronic myeloid leukaemia (CML) proliferation and CML resistance to the drug of choice for CML, the BCR/ABL inhibitor, imatinib. The gene discussed is FYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.